The bioavailability of cytarabine in dogs with meningoencephalitis of unknown etiology through iontophoresis and rectal delivery.
Bioavailability
Cytarabine
Dog
Meningoencephalitis
Journal
Open veterinary journal
ISSN: 2218-6050
Titre abrégé: Open Vet J
Pays: Libya
ID NLM: 101653182
Informations de publication
Date de publication:
Historique:
received:
11
09
2020
accepted:
31
12
2020
entrez:
26
4
2021
pubmed:
27
4
2021
medline:
5
10
2021
Statut:
ppublish
Résumé
Cytarabine (CA) is used to treat dogs with meningoencephalitis of unknown etiology (MUE) by subcutaneous or intravenous administration. The objective was to investigate transdermal iontophoresis and rectal administration as alternative routes of CA delivery. Two client-owned dogs with MUE were studied. The ActivaPatch® IONTOGO™ 12.0 iontophoresis drug delivery system delivered 200 mg/m2 CA transdermally. Blood samples were collected by sparse sampling technique after initiation of the device. At another visit, 100 mg/m2 CA was administered rectally. Blood samples were collected by sparse sampling technique after administration. Plasma CA concentrations were measured by high-pressure liquid chromatography. The concentration of plasma CA after transdermal and rectal administration was below the limits of quantification (0.1 μg/ml) in all samples suggesting inadequate bioavailability with transdermal and rectal administration. Transdermal and rectal CA administration are not reasonable alternative routes of delivery.
Sections du résumé
Background
Cytarabine (CA) is used to treat dogs with meningoencephalitis of unknown etiology (MUE) by subcutaneous or intravenous administration.
Aim
The objective was to investigate transdermal iontophoresis and rectal administration as alternative routes of CA delivery.
Methods
Two client-owned dogs with MUE were studied. The ActivaPatch® IONTOGO™ 12.0 iontophoresis drug delivery system delivered 200 mg/m2 CA transdermally. Blood samples were collected by sparse sampling technique after initiation of the device. At another visit, 100 mg/m2 CA was administered rectally. Blood samples were collected by sparse sampling technique after administration. Plasma CA concentrations were measured by high-pressure liquid chromatography.
Results
The concentration of plasma CA after transdermal and rectal administration was below the limits of quantification (0.1 μg/ml) in all samples suggesting inadequate bioavailability with transdermal and rectal administration.
Conclusion
Transdermal and rectal CA administration are not reasonable alternative routes of delivery.
Identifiants
pubmed: 33898281
doi: 10.4314/ovj.v11i1.6
pii: OVJ-11-36
pmc: PMC8057209
doi:
Substances chimiques
Immunosuppressive Agents
0
Cytarabine
04079A1RDZ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
36-38Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest.
Références
J Small Anim Pract. 2006 Oct;47(10):588-95
pubmed: 17004951
Am J Physiol. 1986 Sep;251(3 Pt 1):G332-40
pubmed: 2875654
J Vet Intern Med. 2007 Jan-Feb;21(1):100-6
pubmed: 17338156
Vet J. 2010 Jun;184(3):290-7
pubmed: 19410487
Pharm Res. 1984 May;1(3):129-34
pubmed: 24277250
Vet J. 2016 Jul;213:1-5
pubmed: 27240905
J Vet Pharmacol Ther. 2018 Oct;41(5):638-643
pubmed: 29761906
J Vet Pharmacol Ther. 2013 Aug;36(4):408-11
pubmed: 22943060
Am J Vet Res. 1995 Dec;56(12):1629-36
pubmed: 8599525
Molecules. 2014 Dec 12;19(12):20780-807
pubmed: 25514222
Curr Drug Deliv. 2007 Jan;4(1):1-10
pubmed: 17269912